<DOC>
	<DOCNO>NCT00195403</DOCNO>
	<brief_summary>The objective investigation identify follow problem question respect safety efficacy Enbrel post-marketing period require Korea Food Drug Administration ( KFDA ) 's regulation . 1 . Unknown adverse reaction , especially serious adverse reaction 2 . Incidences adverse reaction routine drug use 3 . Factors may affect safety drug 4 . Factors may affect efficacy drug This investigation span 3 different study , 0881A-101575 ( alias B1801105 ) NCT00195403 , 0881A-102018 ( alias B1801112 ) NCT00195416 0881A-102212 ( alias B1801113 ) . All study combine record .</brief_summary>
	<brief_title>A Drug Use Investigation ENBREL Post-marketing Surveillance ( PMS ) RA PsA</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Inclusion Criteria Rheumatoid Arthritis Adults : Treatment active rheumatoid arthritis ( RA ) adult response diseasemodifying antirhematic drug ( DMARDs ) , include MTX , inadequate Children : Treatment active polyarticularcourse chronic active rheumatoid arthritis child age 4 17 year inadequate response , prove intolerant , MTX Psoriatic Arthritis Active progressive psoriatic arthritis ( PsA ) adult respond adequately previous DMARDs Exclusion Criteria Patients Enbrel contraindicate per local labeling Patients know hypersensitivity Enbrel component product Patients sepsis risk sepsis Patients active infection include chronic localized infection tuberculosis . ( Treatment Enbrel initiate . )</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
</DOC>